Last update 01 Nov 2024

Ziftomenib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile
+ [3]
Mechanism
MLL1 inhibitors(lysine methyltransferase 2A inhibitors), menin inhibitors(Menin inhibitors), Protein interaction domain and motifs inhibitors
Inactive Indication
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationOrphan Drug (EU), Breakthrough Therapy (US)
Login to view timeline

Structure

Molecular FormulaC33H42F3N9O2S2
InChIKeyBGGALFIXXQOTPY-NRFANRHFSA-N
CAS Registry2134675-36-6

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 2
BE
12 Sep 2019
Acute Myeloid LeukemiaPhase 2
IT
12 Sep 2019
Mixed phenotype acute leukemiaPhase 2
ES
12 Sep 2019
Mixed phenotype acute leukemiaPhase 2
GB
12 Sep 2019
Mixed phenotype acute leukemiaPhase 2
DE
12 Sep 2019
Mixed phenotype acute leukemiaPhase 2
BE
12 Sep 2019
Mixed phenotype acute leukemiaPhase 2
CA
12 Sep 2019
Mixed phenotype acute leukemiaPhase 2
US
12 Sep 2019
Mixed phenotype acute leukemiaPhase 2
IT
12 Sep 2019
Mixed phenotype acute leukemiaPhase 2
FR
12 Sep 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
83
(svffpphcve) = the most common grade 3 or worse treatment-emergent adverse events were anaemia (20 [24%]), febrile neutropenia (18 [22%]), pneumonia (16 [19%]), differentiation syndrome (12 [15%]), thrombocytopenia (11 [13%]), and sepsis (ten [12%]). zuqpcnywbt (umflnockwz )
Positive
01 Oct 2024
Phase 1
20
(rojbseensq) = No differentiation syndrome events of any grade were reported, and no dose-limiting toxicities, evidence of QTc prolongation, drug-drug interactions or additive myelosuppression were observed. hqdogvcbmx (xjkekusxtj )
Positive
30 Jan 2024
(ziftomenib and 7+3)
Phase 1/2
-
(fkyrthfofi) = hlvrounfxw spqilkvxwt (jazpqcbwdb )
-
08 Jun 2023
Phase 1/2
-
(obhbsjplwk) = opcdrdgctp clmwtoduuw (xwfewnjhjt, 0 - 26.5)
Positive
15 Nov 2022
(obhbsjplwk) = vgdeannsmj clmwtoduuw (xwfewnjhjt, 5.5 - 57.2)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free